593 related articles for article (PubMed ID: 18794799)
1. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM
Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799
[TBL] [Abstract][Full Text] [Related]
2. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation.
Sakamoto KM; Kim KB; Verma R; Ransick A; Stein B; Crews CM; Deshaies RJ
Mol Cell Proteomics; 2003 Dec; 2(12):1350-8. PubMed ID: 14525958
[TBL] [Abstract][Full Text] [Related]
3. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
4. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
[TBL] [Abstract][Full Text] [Related]
5. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
[TBL] [Abstract][Full Text] [Related]
6. Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells.
Tang YQ; Han BM; Yao XQ; Hong Y; Wang Y; Zhao FJ; Yu SQ; Sun XW; Xia SJ
Asian J Androl; 2009 Jan; 11(1):119-26. PubMed ID: 19050678
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
8. AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
De Amicis F; Chiodo C; Morelli C; Casaburi I; Marsico S; Bruno R; Sisci D; Andò S; Lanzino M
BMC Cancer; 2019 Nov; 19(1):1038. PubMed ID: 31684907
[TBL] [Abstract][Full Text] [Related]
9. Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor α.
Jiang Y; Deng Q; Zhao H; Xie M; Chen L; Yin F; Qin X; Zheng W; Zhao Y; Li Z
ACS Chem Biol; 2018 Mar; 13(3):628-635. PubMed ID: 29271628
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Dihydrotestosterone and Estradiol Levels by HEXIM1.
Mozar F; Sharma V; Gorityala S; Albert JM; Xu Y; Montano MM
Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34864989
[TBL] [Abstract][Full Text] [Related]
11. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
[TBL] [Abstract][Full Text] [Related]
12. Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.
Hayhow TG; Williamson B; Lawson M; Cureton N; Braybrooke EL; Campbell A; Carbajo RJ; Cheraghchi-Bashi A; Chiarparin E; Diène CR; Fallan C; Fisher DI; Goldberg FW; Hopcroft L; Hopcroft P; Jackson A; Kettle JG; Klinowska T; Künzel U; Lamont G; Lewis HJ; Maglennon G; Martin S; Gutierrez PM; Morrow CJ; Nikolaou M; Nissink JWM; O'Shea P; Polanski R; Schade M; Scott JS; Smith A; Weber J; Wilson J; Yang B; Crafter C
Commun Biol; 2024 May; 7(1):563. PubMed ID: 38740899
[TBL] [Abstract][Full Text] [Related]
13. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.
Fan M; Bigsby RM; Nephew KP
Mol Endocrinol; 2003 Mar; 17(3):356-65. PubMed ID: 12554766
[TBL] [Abstract][Full Text] [Related]
14. Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.
Cyrus K; Wehenkel M; Choi EY; Lee H; Swanson H; Kim KB
ChemMedChem; 2010 Jul; 5(7):979-85. PubMed ID: 20512796
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of niclosamide PROTACs.
Munoz E; Chen G; Hossain A; Wu S; Oceguera Nava E; Hang J; Lee T; Zhang Q; Wang G; Chen QH
Bioorg Med Chem Lett; 2022 Sep; 72():128870. PubMed ID: 35772635
[TBL] [Abstract][Full Text] [Related]
16. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor.
Mafuvadze B; Liang Y; Hyder SM
Oncol Rep; 2014 Oct; 32(4):1727-33. PubMed ID: 25051231
[TBL] [Abstract][Full Text] [Related]
18. Wild-type and specific mutant androgen receptor mediates transcription via 17β-estradiol in sex hormone-sensitive cancer cells.
Susa T; Ikaga R; Kajitani T; Iizuka M; Okinaga H; Tamamori-Adachi M; Okazaki T
J Cell Physiol; 2015 Jul; 230(7):1594-606. PubMed ID: 25536295
[TBL] [Abstract][Full Text] [Related]
19. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
Ohoka N
Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.
Aakula A; Leivonen SK; Hintsanen P; Aittokallio T; Ceder Y; Børresen-Dale AL; Perälä M; Östling P; Kallioniemi O
Mol Oncol; 2015 Aug; 9(7):1287-300. PubMed ID: 25907805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
